Taking people in FranceNo phase
Studying gene mutation patterns in people with myelofibrosis
Studies blood cell mutation patterns in adults with ASXL1-mutated myelofibrosis.
Key facts
- Who runs it
- University Hospital, Angers
- Where
- Angers, Brest, Cholet, Créteil, Marseille, Nantes, Paris, Pessac, Pierre-Bénite, Quimper, Tours, and Vannes, FranceSee the 13 sites
- Trial code
- Registry title
- Clonal Architecture of ASXL1-mutated Myelofibrosis
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 24 Apr 2023
- Expected to end
- 23 Apr 2031
- Type of study
- Interventional
- Treatments tested
- Clonal architecture determination
- Record updated
- 9 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with primary or secondary myelofibrosis whose blood cells carry an ASXL1 gene change. It studies how the disease cells are built up and how that affects the outlook.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Primary or secondary myelofibrosis
- Biomarker or test result
- ASXL1 mutation
Main reasons for not taking part
- Another active blood disease or cancer at the time of diagnosis
- Under a legal protection scheme or unable to give consent
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adults (age ≥18 years),
- Affiliated to the national social security system,
- ASXL1 mutated primary or secondary myelofibrosis,
- Signed the consent to participate in the study,
- Included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM)
Who cannot take part
- Patient with another active hematological disease or cancer at the time of diagnosis,
- Person subject to legal protection scheme or incapable of giving consent
Where in France
- CHU AngersAngers, FranceContact: Corentin ORVAIN, DrTaking people
- CHRU BrestBrest, FranceContact: Jean-Christophe IANOTTO, PrNot yet recruiting
- CH CholetCholet, FranceContact: Charles BESCOND, DrNot yet recruiting
- CHU Henri MondorCréteil, FranceContact: Lydia ROYTaking people
- Institut Paoli-CalmettesMarseille, FranceContact: Jérôme REYTaking people
- CHU NantesNantes, FranceContact: Viviane DUBRUILLE, DrNot yet recruiting
- AP-HP Hôpital Saint LouisParis, FranceContact: Juliette SORET-DULPHYNot yet recruiting
- Hôpital bicêtreParis, FranceContact: Laurence Laurence, DrTaking people
- CHU de BordeauxPessac, FranceContact: Clémence MEDIAVILLATaking people
- CHU LYONPierre-Bénite, FranceContact: Vincent ALCAZERTaking people
- CH de CornouailleQuimper, FranceContact: Lenaïg LE CLECH, DrNot yet recruiting
- CHRU Tours Hopital BretonneauTours, FranceContact: Antoine MACHET, DrTaking people
- CH de VannesVannes, FranceContact: Mélanie MERCIERNot yet recruiting
About the trial
What the trial wants to find out
Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis
The group in the trial
- CLONEMF cohortTreatment being tested
Treatment: Clonal architecture determination
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clonal Architecture of ASXL1-mutated Myelofibrosis
- Plain-language title
- Studying gene mutation patterns in people with myelofibrosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 March 2026